Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 3/20 | 0.31 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605300 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3EPHX1CCR2 | |
| SCHEMBL2125188 | 0.80 | SLC6A9 (0.39) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL2126423 | 0.80 | SLC6A9 (0.39) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL2126165 | 0.80 | SLC6A9 (0.39) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL2605336 | 0.80 | CHRM2 (0.36) | CHRM2CHRM1CHRM3EPHX1CCR2 | |
| SCHEMBL2605306 | 0.80 | CHRM2 (0.36) | CHRM2CHRM1CHRM3EPHX1CCR2 | |
| SCHEMBL2124924 | 0.78 | SLC6A9 (0.37) | — | |
| SCHEMBL23264965 | 0.77 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1CCR2 | |
| SCHEMBL31329480 | 0.77 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1CCR2 | |
| SCHEMBL30200426 | 0.77 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | CHRM2 2988/4885CHRM1 1791/4885CHRM3 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.